My ePortfolio Register   

Technologies for personalised cancer immunotherapies

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.05.16
Views: 1750

Prof James Heath - California Institute of Technology, Pasadena, USA

Prof James Heath speaks with ecancertv at AACR 2016 about neoantigens, a highly-personalised course of immunotherapy.

He explains the process of identifying and isolating mutant markers from a patients genome, to then process these novel targets as a T cell receptors.

He also discusses the current costs of therapy, considering the development of technology in recent years and looking forward to a future of faster, cheaper, patient-specific treatments.

For more on neo-antigens, you can view an interview with Dr Nicholas McGranahan about neoantigens in heterogenous tumours here.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence